Login Register Cart 0
Mini-Review Article

1- [4-（2-氨基乙氧基）苯基羰基] -3,5-双-（苄叉基）-4-哌啶酮类候选抗肿瘤药的发现和研究：我们近15年的研究

卷 28, 期 13, 2021

发表于: 30 July, 2020

页: [2453 - 2464] 页: 12

弟呕挨: 10.2174/0929867327666200730215752

价格: $65

conference banner
摘要

这篇综述概述了我们的实验室在过去的15年中作为潜在药物候选物的一系列新的1- [4-2-氨基乙氧基）苯基羰基] -3,5-双-（亚苄基）-4-哌啶酮（5-8）的发现和开发。这些化合物中有许多表现出优异的细胞毒性，并且通常比当代抗癌药更有效。这些分子中许多的两个非常重要的特征是，第一，更大的肿瘤选择性毒性；第二，这些分子充当多药耐药性调节剂的能力。一些有效化合物的作用方式是通过凋亡诱导，活性氧的产生，某些胱天蛋白酶的活化以及影响线粒体功能。这些分子还显示出有希望的抗疟和抗分枝杆菌特性。在一项短期毒性研究中，这些分子在小鼠中具有良好的耐受性。已经提出了结构活性关系和药物递送系统以及这些化合物的药代动力学研究和代谢稳定性。与该系列（5-8）相关的积极特征值得进一步评估，以作为候选抗肿瘤药物候选物。

关键词: 哌啶酮，不饱和酮，姜黄素，抗癌，细胞毒性，抗疟疾，抗分枝杆菌，多药耐药性。

« Previous Next »
[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
López-Lázaro, M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res., 2008, 52(Suppl. 1), S103-S127.
[http://dx.doi.org/10.1002/mnfr.200700238] [PMID: 18496811]
[3]
Liu, W.; Zhai, Y.; Heng, X.; Che, F.Y.; Chen, W.; Sun, D.; Zhai, G. Oral bioavailability of curcumin: problems and advancements. J. Drug Target., 2016, 24(8), 694-702.
[http://dx.doi.org/10.3109/1061186X.2016.1157883] [PMID: 26942997]
[4]
Das, U.; Sharma, R.K.; Dimmock, J.R. 1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets. Curr. Med. Chem., 2009, 16(16), 2001-2020.
[http://dx.doi.org/10.2174/092986709788682218] [PMID: 19519378]
[5]
Dimmock, J.R.; Kandepu, N.M.; Nazarali, A.J.; Motaganahalli, N.L.; Kowalchuk, T.P.; Pugazhenthi, U.; Prisciak, J.S.; Quail, J.W.; Allen, T.M.; LeClerc, R.; Santos, C.L.; De Clercq, E.; Balzarini, J. Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenyl-methylene]cyclohexanones and related compounds. J. Med. Chem., 2000, 43(21), 3933-3940.
[http://dx.doi.org/10.1021/jm000058o] [PMID: 11052798]
[6]
Gordillo, G.M.; Biswas, A.; Khanna, S.; Spieldenner, J.M.; Pan, X.; Sen, C.K. Multidrug resistance-associated protein-1 (MRP-1)-dependent glutathione disulfide (GSSG) efflux as a critical survival factor for oxidant-enriched tumorigenic endothelial cells. J. Biol. Chem., 2016, 291(27), 14394.
[http://dx.doi.org/10.1074/jbc.A115.688879] [PMID: 27371570]
[7]
Pati, H.N.; Das, U.; Sharma, R.K.; Dimmock, J.R. Cytotoxic thiol alkylators. Mini Rev. Med. Chem., 2007, 7(2), 131-139.
[http://dx.doi.org/10.2174/138955707779802642] [PMID: 17305587]
[8]
Hossain, M.; Das, U.; Dimmock, J.R. Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins. Eur. J. Med. Chem., 2019, 183,111687.
[http://dx.doi.org/10.1016/j.ejmech.2019.111687] [PMID: 31539776]
[9]
Benvenuto, J.A.; Connor, T.H.; Monteith, D.K.; Laidlaw, J.L.; Adams, S.C.; Matney, T.S.; Theiss, J.C. Degradation and inactivation of antitumor drugs. J. Pharm. Sci., 1993, 82(10), 988-991.
[http://dx.doi.org/10.1002/jps.2600821007] [PMID: 8254498]
[10]
Dimmock, J.R.; Arora, V.K.; Wonko, S.L.; Hamon, N.W.; Quail, J.W.; Jia, Z.; Warrington, R.C.; Fang, W.D.; Lee, J.S. 3,5-Bis-benzylidene-4-piperidones and related compounds with high activity towards P388 leukemia cells. Drug Des. Deliv., 1990, 6(3), 183-194.
[PMID: 2076179]
[11]
Das, U.; Alcorn, J.; Shrivastav, A.; Sharma, R.K.; De Clercq, E.; Balzarini, J.; Dimmock, J.R. Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylamino-ethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur. J. Med. Chem., 2007, 42(1), 71-80.
[http://dx.doi.org/10.1016/j.ejmech.2006.08.002] [PMID: 16996657]
[12]
Dimmock, J.R.; Das, U. Antineoplastic compounds. US Patent 7,582,655B2. 2009.
[13]
Thakral, S.; Singh, V. Recent development on importance of heterocyclic amides as potential bioactive molecules: a review. Curr. Bioact. Compd., 2019, 15(3), 316-336.
[http://dx.doi.org/10.2174/1573407214666180614121140]
[14]
Pratt, W.B.; Ruddon, R.W. The anticancer drugs; Oxford University Press: New York, 1979, p. 273.
[http://dx.doi.org/ 10.1002/jps.2600690439]
[15]
Boyd, M.R.; Paull, K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res., 1995, 34(2), 91-109.
[http://dx.doi.org/10.1002/ddr.430340203]
[16]
Das, U.; Sakagami, H.; Chu, Q.; Wang, Q.; Kawase, M.; Selvakumar, P.; Sharma, R.K.; Dimmock, J.R. 3,5-Bis-(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbon-yl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy. Bioorg. Med. Chem. Lett., 2010, 20(3), 912-917.
[http://dx.doi.org/10.1016/j.bmcl.2009.12.076] [PMID: 20064715]
[17]
Robles-Escajeda, E.; Das, U.; Ortega, N.M.; Parra, K.; Francia, G.; Dimmock, J.R.; Varela-Ramirez, A.; Aguilera, R.J. A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol. (Dordr.), 2016, 39(3), 265-277.
[http://dx.doi.org/10.1007/s13402-016-0272-x] [PMID: 26920032]
[18]
Edraki, N.; Das, U.; Hemateenejad, B.; Dimmock, J.R.; Miri, R. Comparative QSAR analysis of 3,5-bis (Arylidene)-4-piperidone derivatives: the development of predictive cytotoxicity models. Iran. J. Pharm. Res., 2016, 15(2), 425-437.
[PMID: 27642313]
[19]
Das, S.; Gul, H.I.; Das, U.; Balzarini, J.; Dimmock, S.G.; Dimmock, J.R. Novel conjugated unsaturated ketones with submicromolar potencies towards some leukemic and colon cancer cells. Med. Chem., 2019, 15(4), 430-438.
[http://dx.doi.org/10.2174/1573406414666181015142633] [PMID: 30324886]
[20]
Sheshkin, D. Handbook of parametric and non-parametric statistical procedures, 2nd ed; Chapman and Hall: London, 2000, pp. 1093-1107.
[21]
Helal, M.; Das, U.; Bandy, B.; Islam, A.; Nazarali, A.J.; Dimmock, J.R. Mitochondrial dysfunction contributes to the cytotoxicity of some 3,5-bis(benzylidene)-4-piperidone derivatives in colon HCT-116 cells. Bioorg. Med. Chem. Lett., 2013, 23(4), 1075-1078.
[http://dx.doi.org/10.1016/j.bmcl.2012.12.016] [PMID: 23305919]
[22]
Contreras, L.; Calderon, R.I.; Varela-Ramirez, A.; Zhang, H.Y.; Quan, Y.; Das, U.; Dimmock, J.R.; Skouta, R.; Aguilera, R.J. Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones. Cell Oncol. (Dordr.), 2018, 41(6), 623-636.
[http://dx.doi.org/10.1007/s13402-018-0397-1] [PMID: 30088262]
[23]
Das, S.; Das, U.; Bandy, B.; Gorecki, D.K.; Dimmock, J.R. The effect of some 1-[4-(2-diethylaminoethoxy)-phenylcarbonyl]-3,5-bis (benzylidene)-4-piperidone methiodides and related compounds on respiration and swelling of rat liver mitochondria. Pharmazie, 2008, 63(11), 827-829.
[PMID: 19069245]
[24]
Das, U.; Selvakumar, P.; Sharma, R.K.; Haas, T.A.; Dimmock, J.R. N-acyl-3,5-bis(arylidene)-4-piperidones and related compounds which stimulate fyn kinase. J. Enzyme Inhib. Med. Chem., 2007, 22(4), 451-455.
[http://dx.doi.org/10.1080/14756360701192515] [PMID: 17847712]
[25]
Aronov, A.M.; Murcko, M.A. Toward a pharmacophore for kinase frequent hitters. J. Med. Chem., 2004, 47(23), 5616-5619.
[http://dx.doi.org/10.1021/jm049793g] [PMID: 15509160]
[26]
Levitzki, A.; Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science, 1995, 267(5205), 1782-1788.
[http://dx.doi.org/10.1126/science.7892601] [PMID: 7892601]
[27]
Singh, R.S.; Das, U.; Auschwitz, J.M.; Leed, S.E.; Hickman, M.R.; Dimmock, J.R.; Alcorn, J. From a cytotoxic agent to the discovery of a novel antimalarial agent. Bioorg. Med. Chem. Lett., 2013, 23(2), 584-587.
[http://dx.doi.org/10.1016/j.bmcl.2012.10.126] [PMID: 23228469]
[28]
Leonard, G.D.; Polgar, O.; Bates, S.E. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs, 2002, 3(11), 1652-1659.
[PMID: 12476969]
[29]
Das, U.; Molnár, J.; Baráth, Z.; Bata, Z.; Dimmock, J.R. 1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance. Bioorg. Med. Chem. Lett., 2008, 18(12), 3484-3487.
[http://dx.doi.org/10.1016/j.bmcl.2008.05.034] [PMID: 18513966]
[30]
Chen, Y.; Pant, A.C.; Simon, S.M. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res., 2001, 61(21), 7763-7769.
[31]
Michel, D.; Chitanda, J.M.; Balogh, R.; Yang, P.; Singh, J.; Das, U.; El-Aneed, A.; Dimmock, J.; Verrall, R.; Badea, I. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. Eur. J. Pharm. Biopharm., 2012, 81(3), 548-556.
[http://dx.doi.org/10.1016/j.ejpb.2012.03.016] [PMID: 22531300]
[32]
Poorghorban, M.; Das, U.; Alaidi, O.; Chitanda, J.M.; Michel, D.; Dimmock, J.; Verrall, R.; Grochulski, P.; Badea, I. Characterization of the host-guest complex of a curcumin analog with β-cyclodextrin and β-cyclodextrin-gemini surfactant and evaluation of its anticancer activity. Int. J. Nanomedicine, 2015, 10, 503-515.
[http://dx.doi.org/10.2147/ijn.s70828]] [PMID: 25609956]
[33]
Singh, R.S.; Das, U.; Dimmock, J.R.; Alcorn, J. A general HPLC-UV method for the quantitative determination of curcumin analogues containing the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore in rat biomatrices. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(28), 2796-2802.
[http://dx.doi.org/10.1016/j.jchromb.2010.08.034] [PMID: 20863771]
[34]
Awad, H.; Stoudemayer, M.J.; Usher, L.; Amster, I.J.; Cohen, A.; Das, U.; Whittal, R.M.; Dimmock, J.; El-Aneed, A. The unexpected formation of [M - H]+ species during MALDI and dopant-free APPI MS analysis of novel antineoplastic curcumin analogues. J. Mass Spectrom., 2014, 49(11), 1139-1147.
[http://dx.doi.org/10.1002/jms.3434] [PMID: 25395129]
[35]
McNaney, C.A.; Drexler, D.M.; Hnatyshyn, S.Y.; Zvyaga, T.A.; Knipe, J.O.; Belcastro, J.V.; Sanders, M. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev. Technol., 2008, 6(1), 121-129.
[http://dx.doi.org/10.1089/adt.2007.103] [PMID: 18336089]
[36]
Das, U.; Das, S.; Bandy, B.; Stables, J.P.; Dimmock, J.R. N-Aroyl-3,5-bis(benzylidene)-4-piperidones: a novel class of antimycobacterial agents. Bioorg. Med. Chem., 2008, 16(7), 3602-3607.
[http://dx.doi.org/10.1016/j.bmc.2008.02.009] [PMID: 18282710]
[37]
Stables, J.P.; Kupferberg, H.J. The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant screening project.In:Molecular and Cellular Targets for Anti-epileptic Drugs; Avanzini, G.; Regesta, G.; Tanganelli, P.; Avoli, M., Eds.; John Sibbey: London, 1997, pp. 191-198.
[38]
Das, U.; Singh, R.S.; Alcorn, J.; Hickman, M.R.; Sciotti, R.J.; Leed, S.E.; Lee, P.J.; Roncal, N.; Dimmock, J.R. 3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum. Bioorg. Med. Chem., 2013, 21(23), 7250-7256.
[http://dx.doi.org/10.1016/j.bmc.2013.09.065] [PMID: 24139941]

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy